Advertisement

Molecular Biology

, Volume 52, Issue 5, pp 715–722 | Cite as

Modulation of Luciferase Production in Melanoma Cells in vitro

  • O. F. Kandarakov
  • A. V. Bruter
  • A. V. Belyavsky
MOLECULAR CELL BIOLOGY

Abstract

Reporter proteins find increasing application in biomedical studies in vitro and in vivo. However, to correctly interpret the results based on their use, it is important to understand whether reporter protein production is modulated in model cells and in what conditions such modulation may occur. Reporter activity was studied in Mel IL melanoma cells transiently transfected with a pCpG vector-based plasmid construct expressing firefly luciferase. Luciferase expression quickly dropped during the first two culture passages, which were followed by a quasi-stable period, when luciferase expression relatively slightly decreased with time. Phases of maximal and minimal luciferase production, which corresponded to the exponential and stationary growth phases, respectively, were observed during batch culture. When the medium was changed, luciferase production was stimulated in the stationary, but not exponential, cell growth phase. Severe hypoxia (0.1% O2) decreased the luciferase amount, suggesting substantial modulation of cell metabolism in total and luciferase production in particular. The targeted drug vemurafenib suppressed the luciferase production in Mel IL cells, whereas DMSO, which is often used as a drug solvent in experiments with cells, stimulated the luciferase production. Based on the results, it was hypothesized that modulation of reporter protein production in mammalian cells reflects the adaptation of intracellular metabolism to external conditions and may be a source of incorrect interpretations of experiments using reporter proteins.

Keywords:

luciferase plasmid melanoma hypoxia DMSO vemurafenib 

Notes

ACKNOWLEDGMENTS

We are grateful to researchers of the Blokhin Cancer Research Center (Russian Academy of Medical Sciences) for kindly providing the Mel IL cell line and vemurafenib.

This work was supported by the Russian Science Foundation (project no. 14-35-00107-P). The results shown in Fig. 1 were obtained with support from the Program of Basic Research at State Academies of Sciences from 2013 to 2020 (project no. 01201363823).

REFERENCES

  1. 1.
    Ginn S.L., Alexander I.E., Edelstein M.L., Abedi M.R., Wixon J. 2013. Gene therapy clinical trials worldwide to 2012: An update. J. Gene Med. 15, 65–77.CrossRefPubMedGoogle Scholar
  2. 2.
    Yin H., Kanasty R.L., Eltoukhy A.A., Vegas A.J., Dorkin J.R., Anderson D.G. 2014. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555.CrossRefPubMedGoogle Scholar
  3. 3.
    Gill D.R., Pringle I.A., Hyde S.C. 2009. Progress and prospects: The design and production of plasmid vectors. Gene Ther. 16, 165–171.CrossRefPubMedGoogle Scholar
  4. 4.
    Bruter A.V., Kandarakov O.F., Belyavsky A.V. 2018. Persistence of plasmid-mediated expression of transgenes in human mesenchymal stem cells depends primarily on CpG levels of both vector and transgene. J. Gene Med. 20, e3009. doi 10.1002/jgm.3009CrossRefPubMedGoogle Scholar
  5. 5.
    Okita K., Nakagawa M., Hyenjong H., Ichisaka T., Yamanaka S. 2008. Generation of mouse induced pluripotent stem cells without viral vectors. Science. 322, 949–953.CrossRefPubMedGoogle Scholar
  6. 6.
    Leitậ̣̣̣̣̣o J.M.M., Esteves da Silva J.C.G. 2010. Firefly luciferase inhibition. J. Photochem. Photobiol. B. 101, 1–8. doi 10.1016/j.jphotobiol.2010.06.015CrossRefPubMedGoogle Scholar
  7. 7.
    Doran D.M., Kulkarni-Datar K., Cool D.R., Brown T.L. 2011. Hypoxia activates constitutive luciferase reporter constructs. Biochimie. 93, 361–368.CrossRefPubMedGoogle Scholar
  8. 8.
    Keyaerts M., Remory I., Caveliers V., Breckpot K., Bos T.J., Poelaert J., Bossuyt A., Lahoutte T. 2012. Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. PLoS One. 7, e30061.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Khalil A.A., Jameson M.J., Broaddus W.C., Lin P.S., Dever S.M., Golding S.E., Rosenberg E., Valerie K., Chung Th.D. 2013. The influence of hypoxia and pH on bioluminescence imaging of luciferase-transfected tumor cells and xenografts. Int. J. Mol. Imaging. 2013, ID 287697. http://dx.doi.org/.10.1155/2013/287697.Google Scholar
  10. 10.
    Pirt S.J. 1975. Principles of Microbe and Cell Cultivation. London: Blackwell.Google Scholar
  11. 11.
    Kandarakov O.F., Kopantseva E.E., Belyavsky A.V. 2016. Analysis of proliferation of melanoma cells and mesenchymal stem cells in co-culture and contribution of experimental conditions into interpretation of the results. Bull. Exp. Biol. Med. 162, 127–133.CrossRefPubMedGoogle Scholar
  12. 12.
    Fallahi-Sichani M., Honarnejad S., Heiser L.M., Gray J.W., Sorger P.K. 2013. Metrics other than potency reveal systematic variation in responses to cancer drugs. Nat. Chem. Biol. 9, 708–714.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Swaika A., Crozier J.A., Joseph R.W. 2014. Vemurafenib: An evidence-based review of its clinical utility in the treatment of metastatic melanoma. Drug Des. Devel. Ther. 16, 775–787.Google Scholar
  14. 14.
    Thaler R., Spitzer S., Karlic H., Klaushofer K., Varga F. 2012. DMSO is a strong inducer of DNA hydroxymethylation in pre-osteoblastic MC3T3-E1 cells. Epigenetics. 7, 635–651.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kaskova Z.M., Tsarkova A.S., Yampolsky I.V. 2016. 1001 lights: Luciferins, luciferases, their mechanisms of action and applications in chemical analysis, biology and medicine. Chem. Soc. Rev. 45, 6048–6077.CrossRefPubMedGoogle Scholar
  16. 16.
    Jenke A.C., Stehle I.M., Herrmann F., Eisenberger T., Baiker A., Bode J., Fackelmayer F.O., Lipps H.J. 2004. Nuclear scaffold/matrix attached region modules linked to a transcription unit are sufficient for replication and maintenance of a mammalian episome. Proc. Natl. Acad. Sci. U. S. A. 101, 11 322–11 327.CrossRefGoogle Scholar
  17. 17.
    Würtele H., Little K.C., Chartrand P. 2003. Illegitimate DNA integration in mammalian cells. Gene Ther. 10, 1791–1799.CrossRefPubMedGoogle Scholar
  18. 18.
    Izsvák Z., Chuah M.K., Vandendriessche T., Ivics Z. 2009. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods. 49, 287–297.CrossRefPubMedGoogle Scholar
  19. 19.
    Neuhuber B., Swanger S.A., Howard L., Mackay A., Fischer I. 2008. Effects of plating density and culture time on bone marrow stromal cell characteristics. Exp. Hematol. 36, 1176–1185.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Moriyama E.H., Niedre M.J., Jarvi M.T., Mocanu J.D., Moriyama Y., Subarsky P., Li B., Lilge L.D., Wilson B.C. 2008. The influence of hypoxia on bioluminescence in luciferase-transfected gliosarcoma tumor cells in vitro. Photochem. Photobiol. Sci. 7, 675–680.CrossRefPubMedGoogle Scholar
  21. 21.
    Brutkiewicz S., Mendonca M., Stantz K., Comerford K., Bigsby R., Hutchins G., Goebl M., Harrington M. 2007. The expression level of luciferase within tumour cells can alter tumour growth upon in vivo bioluminescence imaging. Luminescence. 22, 221–228.CrossRefPubMedGoogle Scholar
  22. 22.
    Beazley-Long N., Gaston K., Harper S.J., Orlando A., Bates D.O. 2015. Novel mechanisms of resistance to vemurafenib in melanoma: V600E B-Raf reversion and switching VEGF-A splice isoform expression. Am. J. Cancer Res. 5, 433–441.PubMedGoogle Scholar
  23. 23.
    Kalra J., Anantha M., Warburton C., Waterhouse D., Yan H., Yang Y., Strut D., Osooly M., Masin D., Bally M.B. 2011. Validating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhibitor, QLT02. Cancer Biol. Ther. 11, 826–838.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Pleiades Publishing, Inc. 2018

Authors and Affiliations

  • O. F. Kandarakov
    • 1
    • 2
  • A. V. Bruter
    • 1
    • 2
  • A. V. Belyavsky
    • 1
  1. 1.Engelhardt Institute of Molecular Biology, Russian Academy of SciencesMoscowRussia
  2. 2.Blokhin Cancer Research Center, Russian Academy of Medical SciencesMoscowRussia

Personalised recommendations